Previous 10 | Next 10 |
Epilepsia publishes two-year open-label extension Marigold trial data of ZTALMY ® (ganaxolone) oral suspension CV in patients with CDKL5 deficiency disorder (CDD) In preliminary results from a Phase 1 multiple ascending dose (MAD) study, the second generation ganaxolone formula...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 6th Annua...
2023-11-07 14:00:06 ET Marinus Pharmaceuticals, Inc. (MRNS) Q3 2023 Earnings Conference Call November 07, 2023, 08:30 ET Company Participants Sonya Weigle - SVP, IR Scott Braunstein - CEO, President & Chairman Christina Shafer - Chief Commercial Officer J...
2023-11-07 13:31:50 ET More on Marinus Evaluating Marinus: Ztalmy's Growth And Upcoming Trial Insights Marinus Pharmaceuticals, Inc. (MRNS) Q2 2023 Earnings Call Transcript Marinus Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation Marinus P...
2023-11-07 07:07:28 ET More on Marinus Pharmaceuticals Evaluating Marinus: Ztalmy's Growth And Upcoming Trial Insights Marinus Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation Marinus Pharmaceuticals Q3 2023 Earnings Preview Marinus stock ...
ZTALMY ® (ganaxolone) Q3 net product revenue of $5.4 million; 2023 net product revenue guidance increased to between $18.5 and $19 million Over 75% of patients required for the interim analysis are now enrolled in the Phase 3 RAISE trial in refractory status epilepticus; if the trial...
ZTALMY is approved by the U.S. Food and Drug Administration and the European Commission for appropriate patients with CDKL5 deficiency disorder The program enables physicians to request ZTALMY for eligible patients in geographies where the product is not commercially available and as supp...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Marinus Pharmaceuticals Inc. (MRNS) is expected to report $-0.67 for Q3 2023
2023-11-06 11:30:48 ET More on Marinus Pharmaceuticals Evaluating Marinus: Ztalmy's Growth And Upcoming Trial Insights Marinus stock jumps 11% on financial, pipeline updates Marinus downgraded by Oppenheimer on concerns over seizure asset trial For further de...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...